Actively Recruiting
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease
Led by Assiut University · Updated on 2024-08-16
100
Participants Needed
1
Research Sites
3 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital on AF patients with structural heart disease. Eplerenone 25 mg daily will be given and searching for AF recurrence among study population.
CONDITIONS
Official Title
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with non-valvular atrial fibrillation who underwent cardioversion to sinus rhythm either medical, electrical, or spontaneous
You will not qualify if you...
- Patients with rheumatic heart disease
- Thyroid dysfunction
- Wolf-Parkinson-White (WPW) syndrome
- Renal impairment
- Hyperkalemia
- Acute coronary syndrome
- Pregnancy
- Left ventricular dysfunction with ejection fraction less than 40%
- Current use of eplerenone
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Assiut University Heart Hospital
Asyut, Egypt, 71526
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here